Plain-English translation of NCT05214391 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to treat immune thrombocytopenia (ITP)—a condition where your immune system attacks your platelets, causing dangerously low platelet counts and bleeding problems. The study will enroll about 30 patients who haven't responded well to standard treatments. Researchers want to see if this medication can help raise platelet counts and reduce bleeding.
Many people with ITP don't respond well to current treatments, and those who do often need to take medications long-term, which affects their quality of life. This medication works differently than standard treatments by targeting immune cells in a new way, and early research suggests it may help patients whose ITP hasn't improved with conventional therapies.
You likely qualify if…
You likely don't qualify if…
You would take at a dose determined by the research team for the duration of the study. You would need to attend clinic visits for blood tests to monitor your platelet count, liver and kidney function, and overall response to the medication. The study team will track whether your platelet count improves and watch for any side effects.
AI-generated summary from trial data · Aug 26, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Enrollment target
~30 participants
Started
February 2022
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yunfei Chen
Chinese Academy of Medical Science and Blood Disease Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.